Prostate Cancer NEWS You Can Use  
 
Us TOO news e-messages
 Us TOO Prostate Cancer NEWS You Can Use

ASTELLAS -U.S. FDA Approves New Indication for the Use of XTANDI (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer
ENP Newswire - 11 September 2014 Release date- 11092014 - SAN FRANCISCO, CA and TOKYO, JAPAN - Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (Tokyo: 4503) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). This new ...

Presidential Proclamation -- National Prostate Cancer Awareness Month, 2014
NATIONAL PROSTATE CANCER AWARENESS MONTH, 2014 - - - - - - - BY THE PRESIDENT OF THE UNITED STATES OF AMERICA A PROCLAMATION Prostate cancer is one of the most common cancers among American men. They are fathers, brothers, and sons -- and this year, more than 230,000 of them are expected to be diagnosed with this disease. During National Prostate Cancer Awareness Month, we honor all those ...

RNA sequence could help doctors to tailor unique prostate cancer treatment programs
By a News Reporter-Staff News Editor at Cancer Weekly -- Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the open access journal Genome Biology. Because a tumor's RNA shows the real time changes a treatment is causing, the authors think this could be a useful tool to aid diagnosis and predict ...

New recommendations for post-treatment care of prostate cancer survivors
By a News Reporter-Staff News Editor at Cancer Weekly -- Many of the more than 2.5 million men in the U.S. who have received treatment for prostate cancer deal with the often disabling side effects of surgery and radiation and hormonal therapies. To aid in the transition of these patients from specialty to primary care for long-term management of problems such as urinary incontinence and ...

Prostate cancer drug candidate shows great promise
Sept. 06--A white powdered chemical compound emerged from two University of Maryland School of Medicine laboratories more than 10 years ago with a name destined for oblivion, but a future that now looks promising as a treatment for the most challenging cases of prostate cancer. Today VN/124-1 is a drug candidate with a name, galeterone, a pharmaceutical company founded on its potential, and a ...

New Prostate Cancer Study Findings Reported from University of Kentucky (Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate...
New Prostate Cancer Study Findings Reported from University of Kentucky (Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer) By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Oncology have been presented. According to news reporting out of Lexington, Kentucky, by NewsRx editors, research stated, "The role of the androgen receptor (AR) ...

Version 2.0 of Prostate Cancer Risk Calculator now online, complete with emojis
By a News Reporter-Staff News Editor at Cancer Weekly -- A calculator to help men and their doctors assess their risk of prostate cancer, developed at the UT Health Science Center, has had a major upgrade to enhance how men and their physicians better understand a man's risk of prostate cancer (see also Prostate Cancer). A description of the update's needs and benefits is described by the ...

Tests could help men with prostate cancer
TESTING for an abnormal protein in the blood could identify men with prostate cancer who cannot be helped by two new drugs. Patients whose tumours contain a shortened protein called AR-V7 do not respond to enzalutamide and abiraterone, research has shown. The protein is detectable in the blood, raising the possibility of a test that could help doctors plan the best form of treatment for men ...

Blood test for 'nicked' protein predicts prostate cancer treatment response
By a News Reporter-Staff News Editor at Cancer Weekly -- Prostate cancer patients whose tumors contain a shortened protein called AR-V7, which can be detected in the blood, are less likely to respond to two widely used drugs for metastatic prostate cancer, according to results of a study led by researchers at the Johns Hopkins Kimmel Cancer Center. If large-scale studies validate the findings, ...

ASCO and Cancer Care Ontario Issue New Guideline on Treating Metastatic Castration-Resistant Prostate Cancer
ALEXANDRIA, Va., Sept. 8 -- The American Society of Clinical Oncology issued the following news release: The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) today issued a joint clinical practice guideline on treating men with metastatic castration-resistant prostate cancer (CRPC). The guideline includes recommendations on systemic therapies that are indicated for ...

New Prostate Cancer Study Results Reported from Johns Hopkins University School of Medicine (The role of inflammation in prostate cancer)
By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Oncology have been published. According to news reporting originating in Baltimore, Maryland, by NewsRx journalists, research stated, "In the United States and in 'Westernized' countries, the prevalence of both prostate cancer and prostate inflammation is very high, indicating that the two pathologies could be ...

Men who are uneducated about their prostate cancer have difficulty making good treatment choices
By a News Reporter-Staff News Editor at Cancer Weekly -- They say knowledge is power, and a new UCLA study has shown this is definitely the case when it comes to men making the best decisions about how to treat their prostate cancer (see also Prostate Cancer). UCLA researchers found that men who aren't well educated about their disease have a much more difficult time making treatment ...

Age and Genetics Play a Key Role in Prostate Cancer Occurrence
By a News Reporter-Staff News Editor at Cancer Weekly -- For most men, prostate cancer is a concern after the age of 55. While the majority of prostate cancer diagnoses occur among that age group, prostate cancer does get diagnosed in men before then, and we are starting to determine reasons why. In a recent study of early onset prostate cancer out of the University of Michigan, it was found ...

Fighting prostate cancer with a tomato-rich diet
By a News Reporter-Staff News Editor at Cancer Weekly -- Men who eat over 10 portions a week of tomatoes have an 18 per cent lower risk of developing prostate cancer, new research suggests (see also Prostate Cancer). With 35,000 new cases every year in the UK, and around 10,000 deaths, prostate cancer is the second most common cancer in men worldwide. Rates are higher in developed countries, ...

Screening for prostate cancer reduces deaths by 20pc
Washington, August 7 (ANI): A new study has shown that screening for prostate cancer could reduce deaths from the disease by about a fifth. According to the long-term results of a major European study, screening appeared to reduce prostate cancer deaths by 15 percent at 9 years, and this improved to 22 percent at 11 years, and the risk of advanced prostate cancer was also smaller in the ...

Feeling Down May Up Prostate Cancer Risks
NEW YORK, NY -- (Marketwired) -- 07/31/14 -- A prostate cancer diagnosis requires immediate care and consultation with a prostate cancer expert to determine the adequate care needed for the condition. Sadly, of the number of individuals diagnosed with prostate cancer in the U.S., many die from the disease. While it is very common to correlate the numbers that have fallen to prostate cancer ...

U-M research: Late-stage prostate cancer increasing among younger men
July 17--Diagnoses of late-stage prostate cancer among younger men are on a surprising increase, with a nearly sixfold rise in diagnoses over two decades -- too much of an increase to link solely to better screening, according to a team of researchers at the University of Michigan Comprehensive Cancer Center . That, has the U-M researchers calling for a closer look at the DNA of prostate ...

Age and Genetics Play a Key Role in Prostate Cancer Occurrence
NEW YORK, NY -- (Marketwired) -- 08/05/14 -- For most men, prostate cancer is a concern after the age of 55. While the majority of prostate cancer diagnoses occur among that age group, prostate cancer does get diagnosed in men before then, and we are starting to determine reasons why. In a recent study of early onset prostate cancer out of the University of Michigan, it was found that genetics ...

Research questions prostate cancer care
July 15--Two new prostate cancer studies have found that many low-risk patients have been receiving more treatment than is needed or helpful -- racking up millions of dollars in excess health-care costs and, potentially, causing more physical harm than good. One of the studies, both of which were published Monday in JAMA Internal Medicine, showed that among patients whose cancer was not ...

Genomic analysis of prostate cancer indicates best course of action after surgery
By a News Reporter-Staff News Editor at Biotech Week -- (PHILADELPHIA) - There is controversy over how best to treat patients after they've undergone surgery for prostate cancer. Does one wait until the cancer comes back or provide men with additional radiation therapy to prevent cancer recurrence? Now, a new study from Thomas Jefferson University shows that a genomic tool can help doctors and ...

Study finds diagnosing physicians influence therapy decisions for prostate cancer patients
By a News Reporter-Staff News Editor at Biotech Week -- New research from The University of Texas MD Anderson Cancer Center is shedding light on the important role a diagnosing urologist plays in whether older men with low-risk prostate cancer receive treatment for their disease, and if so, the type of treatment they receive as a result (see also Prostate Cancer). The findings, published in ...

New Findings on Prostate Cancer Described by Investigators at Johns Hopkins University (Enhancement of the T-cell Armamentarium as a Cell-Based...
New Findings on Prostate Cancer Described by Investigators at Johns Hopkins University (Enhancement of the T-cell Armamentarium as a Cell-Based Therapy for Prostate Cancer) By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Oncology are discussed in a new report. According to news reporting originating from Baltimore, Maryland, by NewsRx correspondents, research ...

Reports from University of Colorado Advance Knowledge in Health Insurance [Ethnic minorities (African American and Hispanic) males prefer prostate...
Reports from University of Colorado Advance Knowledge in Health Insurance [Ethnic minorities (African American and Hispanic) males prefer prostate cryoablation as.aggressive treatment of localized prostate cancer] By a News Reporter-Staff News Editor at Insurance Weekly News -- Data detailed on Health Insurance have been presented. According to news reporting from Aurora, Colorado, by ...

Does cycling increase risk for erectile dysfunction, infertility, or prostate cancer?
By a News Reporter-Staff News Editor at Clinical Trials Week -- Cycling is a popular activity that offers clear health benefits, but there is an ongoing controversy about whether men who ride have a higher risk of urogenital disorders such as erectile dysfunction, infertility, or prostate cancer. The results of a study of nearly 5,300 male cyclists who participated in the Cycling for Health UK ...

Vasectomy may increase risk of aggressive prostate cancer
By a News Reporter-Staff News Editor at Cancer Weekly -- Boston, MA - Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer according to a new study from Harvard School of Public Health (HSPH). The researchers found that the association remained even among men who received regular PSA screening, suggesting the ...

Cancer Network Highlights the Top Stories From the 2014 ASCO Annual Meeting
NORWALK, Conn., June 17, 2014 /PRNewswire/ -- UBM Medica US announces that Cancer Network, a leading online community for oncologists, presents exclusive coverage of the American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3 in Chicago. This year, the ASCO Annual Meeting brought together more than 30,000 oncology professionals from a broad range of specialties to share ...

Studies from Department of Surgery in the Area of Prostate Cancer Reported (Incidence of Groin Hernia Repair After Radical Prostatectomy A...
Studies from Department of Surgery in the Area of Prostate Cancer Reported (Incidence of Groin Hernia Repair After Radical Prostatectomy A Population-Based Nationwide Study) By a News Reporter-Staff News Editor at Biotech Week -- A new study on Oncology is now available. According to news reporting originating from Ostersund, Sweden, by NewsRx correspondents, research stated, "To assess the ...

NCI -Vasectomy may increase risk of aggressive prostate cancer
ENP Newswire - 11 July 2014 Release date- 10072014 - Boston, MA-Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer according to a new study from Harvard School of Public Health (HSPH). The researchers found that the association remained even among men who received regular PSA screening, suggesting the increased ...

Astellas Details Pipeline Progress at R&D Meeting
TOKYO, July 11, 2014 /PRNewswire/ -- Astellas today announced progress on the Company's efforts to reshape its research framework at its R&D meeting held in Tokyo on July 10. The meeting provided an opportunity for Astellas to present a comprehensive overview of its late-stage clinical programs and corporate strategy. The purpose of the meeting was to provide an update on the initiatives for ...

Secretary Paige Asks President to Light White House Blue for Prostate Cancer
Houston, TX (PRWEB) June 17, 2014 The Honorable Dr. Rod Paige, United States Secretary of Education (2001-2005), joins the growing list of high-profile supporters for the movement to light the White House blue for an evening during September's Prostate Cancer Awareness Month. On why the movement resonated with him, Dr. Paige says, "I am a survivor of prostate cancer, the second leading cancer ...

Living with a Disability Magazine Marks National Men's Health Awareness Month with Article on How Prostate Cancer can Be a Disabling Condition
San Antonio. TX (PRWEB) June 25, 2014 To mark National Men's Health Awareness Month, which occurs every June, the Editorial Board of Living with a Disability magazine has published an important new article on how prostate cancer can become a disabling condition. As the article highlights, prostate cancer is considered a disability by the Social Security Administration for those afflicted with ...

AdMeTech Foundation: Massachusetts Legislators Approve Key Funding for Prostate Cancer Awareness Campaign
BOSTON, July 1, 2014 /PRNewswire-USNewswire/ -- The Massachusetts' House of Representatives and Senate today placed the state in a national leadership position by creating a new education and awareness program dedicated to prostate cancer. The $500,000 campaign, contained in the conference committee report of the FY15 budget, is aimed at saving lives, improving quality of life, and reducing ...

Astellas and Medivation Receive Priority Review from FDA for XTANDI® (Enzalutamide) Capsules In Chemotherapy-Naive Advanced Prostate Cancer
TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) to extend the indication for XTANDI® (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer ...

Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer
JERUSALEM & VANCOUVER, British Columbia & BOTHELL, Wash.--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) today announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in ...

Genomic Health Announces Presentation of Multiple Oncotype DX® Studies in Breast, Prostate, Colon and Renal Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place in Chicago. New data, including two oral presentations, ...

Nymox Announces Positive New Prostate Cancer Clinical Trial Results
HASBROUCK HEIGHTS, N.J., May 6, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today new positive outcome results from the Company's ongoing prospective trial of NX-1207 for the treatment of low grade localized prostate cancer. These are the first clinical patient treatment outcome results for this trial. A controlled comparison was conducted of patients who ...

IsoRay's Cancer Fighting Cesium-131 Isotope in Published Report Shows Significant Results in Early Clinical Interstitial Implants for Gynecologic...
IsoRay's Cancer Fighting Cesium-131 Isotope in Published Report Shows Significant Results in Early Clinical Interstitial Implants for Gynecologic Malignancies IsoRay CEO Dwight Babcock commented, "We are very excited to have our Cesium-131 isotope seeds chosen for use in the treatment of gynecologic cancers. We believe our marketing is most successful by teaming up with medical industry ...

Prostate Cancer: Watch and Wait or Ignore and Wait?
NEW YORK, NY -- (Marketwired) -- 04/25/14 -- A long-term European study highlighted key patient compliance issues in the prostate cancer active surveillance strategy. In lieu of proactive prostate cancer treatments such as robotic prostate surgery, hormone therapy, or radiation, some men choose to postpone treatment and monitor the progression of their disease. Researchers found that one ...

BPH Patients Are Not Safe Taking Testosterone, While Dr. Allen's Device Terminates Prostate Enlargement and Increases Energy Naturally, States Fine Treatment
London, GB (PRWEB) May 03, 2014 Fine Treatment recommends that a man with benign prostatic hyperplasia (BPH) should use Dr. Allen's Device in the first place, as it diminishes the enlarged prostate size naturally relieving lower urinary tract symptoms and increasing male energy. At the same time, commonly used to boost a man's energy testosterone, according to the article in the WWL-News, it ...

Vitamin D: A Sunny Outlook for Prostate Cancer
NEW YORK, NY -- (Marketwired) -- 05/08/14 -- Vitamin D deficiency could be a predictor for aggressive prostate cancer, according to a study funded by The National Institutes of Health and the U.S. Department of Defense. In examining the prostate biopsy results of men with abnormal prostate-specific antigen (PSA) levels and/or digital rectal exams (DREs), researchers discovered that men with ...

New Model Can Predict Therapy Outcomes in Prostate Cancer with Bone Metastasis
PHILADELPHIA, May 1 -- The American Association for Cancer Research issued the following news release: A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients with this disease, according to data published in Cancer Research, a journal of the American ...

Memorial Sloan-Kettering's Dr. Howard Scher Reaffirms Commitment to Lead Phase I Trials for AV Therapeutics' Prostate Cancer Drug
NEW YORK, May 7, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief, Genitourinary Oncology Service and D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, reaffirmed his commitment to lead AV Therapeutics' Phase I clinical trial ...

Prostate Cancer Foundation Receives over $8.4M Movember Donation
SANTA MONICA, Calif.--(BUSINESS WIRE)-- The Prostate Cancer Foundation (PCF) has received over $8.4 million from its partner Movember, the global men’s health charity that gets men to grow and women to support the moustache for the month of November, raising vital funds and awareness for men’s health. PCF will allocate the over $8.4 million to find better treatments and ultimately a cure, by ...

MRI-Guided Prostate Biopsy Improves Accuracy and Patient Comfort
NEW YORK, NY -- (Marketwired) -- 04/07/14 -- During trial, a new MRI-guided prostate biopsy yielded more targeted prostate tissue retrieval and improved diagnosis accuracy. The combined multiparametric magnetic resonance imaging (mpMRI) and magnetic resonance (MR) guided biopsy (MRGB) techniques reduced the incidence of low-risk prostate cancer diagnosis and improved overall detection of ...

Six months hormone therapy in addition to radiotherapy improves prostate cancer survival
By a News Reporter-Staff News Editor at Clinical Trials Week -- Vienna, Austria: Men with prostate cancer that is small and confined to the prostate gland but that is at risk of growing and spreading, do better if they are treated with radiotherapy combined with androgen deprivation therapy, which lowers their levels of the male hormone, testosterone, according to new research (see also ...

Surgery may be best for young men with prostate cancer
Younger men who have been diagnosed with prostate cancer may do well to consider surgery over so-called ”watchful waiting,“ a new study shows. The new research, published in the New England Journal of Medicine, is unlikely to end the long-running debate in the medical community over if and when surgery to remove the prostate is needed - particularly since the men in the study were diagnosed ...

Younger men with prostate cancer did well after surgery
Prostate cancer surgery improved survival among men diagnosed at a younger age or with intermediate-risk disease, U.S. and Swedish researchers say. Study co-author Jennifer Rider of the Harvard School of Public Health and assistant professor of medicine at Brigham and Women's Hospital, and colleagues at the Uppsala University Hospital in Sweden used data from the Scandinavian Prostate Cancer ...

New test detects prostate cancer recurrence with much more accuracy
Washington, Apr 6 (ANI): Researchers in Canada have developed a new genetic "signature" to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy. Professor Robert Bristow said that although surgery and precision radiotherapy are the mainstays of treatment for cancer that is confined to the prostate, the cancer will return in between ...

Medication does not help prevent ED following radiation therapy for prostate cancer
By a News Reporter-Staff News Editor at Cancer Weekly -- Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a study in the April 2 issue of JAMA. Erectile dysfunction (ED) is a common condition resulting from many causes, including prostate cancer ...

Radium-223 dichloride in prostate cancer: Major added benefit for certain patients
By a News Reporter-Staff News Editor at Clinical Trials Week -- Radium-223 dichloride (radium-223 for short, trade name: Xofigo) has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and symptomatic bone metastases, but without visceral metastases. In an early benefit assessment pursuant to the Act on the Reform of the ...

 
 

Facebook - UsToo.org  Twitter - UsToo.org  LinkedIn - UsToo.org Inspire prostate cancer discussions – UsToo.org 

Contact Us | Privacy Policy | Terms & Conditions | Disclaimer   

 
Copyright © 2005-2014 Us TOO International, Inc.
Designed and hosted by ACCESS Medical Group, Ltd.